• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Stu

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2024 Sep 19;11(10):ofae547.
doi: 10.1093/ofid/ofae547. eCollection 2024 Oct. Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity

Alena Chalupka[SUP] 1 2 [/SUP], Uwe Riedmann[SUP] 1 [/SUP], Lukas Richter[SUP] 2 3 [/SUP], Ali Chakeri[SUP] 2 4 [/SUP], Ziad El-Khatib[SUP] 2 [/SUP], Martin Sprenger[SUP] 5 [/SUP], Verena Theiler-Schwetz[SUP] 1 [/SUP], Christian Trummer[SUP] 1 [/SUP], Peter Willeit[SUP] 6 7 8 [/SUP], Harald Schennach[SUP] 9 [/SUP], Bernhard Benka[SUP] 2 [/SUP], Dirk Werber[SUP] 2 [/SUP], Tracy Beth Høeg[SUP] 10 11 [/SUP], John P A Ioannidis[SUP] 12 [/SUP], Stefan Pilz[SUP] 1 [/SUP]



Affiliations
Abstract

Background: We aimed to evaluate the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in previously SARS-CoV-2-infected adults in the general population of Austria during the Delta wave and with extended follow-up.
Methods: In a nationwide retrospective cohort study, we calculated age-, sex-, and nursing home residency-adjusted Cox proportional hazard ratios (HRs) of coronavirus disease 2019 (COVID-19) deaths, SARS-CoV-2 infections, and non-COVID-19 deaths from 1 October to 31 December 2021, and secondarily with extended follow-up to 30 June 2022. Relative vaccine effectiveness (rVE) is rVE = (1 - HR) × 100.
Results: Among 494 646 previously infected adults, 169 543 had received 2 vaccine doses, 133 567 had received 1 dose, and 190 275 were unvaccinated at baseline. We recorded 17 COVID-19 deaths (6 vaccinated, 11 unvaccinated) and 8209 SARS-CoV-2 infections. Absolute risk of COVID-19 deaths was 0.003%. rVE estimates for COVID-19 deaths and reinfections exceeded 75% until the end of 2021 but decreased substantially with extended follow-up. The risk of non-COVID-19 death was lower in those vaccinated versus unvaccinated.
Conclusions: First and second SARS-CoV-2 vaccine doses appear effective in the short-term, but with diminishing effectiveness over time. The extremely low COVID-19 mortality, regardless of vaccination, indicates strong protection of previous infection against COVID-19 death. Lower non-COVID-19 mortality in the vaccinated population might suggest a healthy vaccinee bias.

Keywords: COVID-19; SARS-CoV-2; mortality; observational study; vaccine.

 
Back
Top Bottom